Nutra Pharma Corp.
NPHCOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1431945
P/E Ratio—
52W High$0.005
52W Low$0.0001
Nutra Pharma Corp. (NPHC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NPHC · earnings · updated Jun 10, 2026
Latest Earnings
Q3 FY2022Report Date: Sep 30, 2022EPS Actual
$0.00
Revenue
$0.00B
Fiscal Period
Q3 FY2022
FY ends December
Report Date
Sep 30, 2022
After Market Close
NPHC reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2025 | Oct 23, 2025 | — | — | — | — | — | — |
| — Q3 FY2022 | Sep 30, 2022 | — | $0.00 | — | $0.00B | — | — |
| — Q3 FY2022 | Aug 22, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2021 | Nov 10, 2021 | — | $0.00 | — | $0.00B | — | — |
| — Q2 FY2021 | Jun 30, 2021 | — | $0.00 | — | $0.00B | — | — |
| — Q1 FY2021 | Mar 31, 2021 | — | -$0.00 | — | $0.00B | — | — |
Q4 FY2025
Oct 23, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Sep 30, 2022
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Aug 22, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2022
Mar 31, 2022
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Dec 31, 2021
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Nov 10, 2021
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2021
Jun 30, 2021
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2021
Mar 31, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2022 | Sep 30, 2022 | — | $0.00 | $0.00 | +0.00% |
| — Q3 FY2022 | Aug 22, 2022 | — | $0.00 | $0.00 | +0.00% |
| — Q1 FY2022 | Mar 31, 2022 | — | $0.00 | $0.00 | -26.67% |
| — Q4 FY2021 | Dec 31, 2021 | — | $0.00 | $0.00 | +11.11% |
| — Q4 FY2021 | Nov 10, 2021 | — | $0.00 | $0.00 | +10.00% |
| — Q2 FY2021 | Jun 30, 2021 | — | $0.01 | $0.01 | -2.99% |
| — Q1 FY2021 | Mar 31, 2021 | — | $0.01 | $0.01 | +5.19% |
| — Q4 FY2020 | Dec 31, 2020 | — | $0.00 | $0.00 | +0.00% |
Q3 FY2022+0.00%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q3 FY2022+0.00%
Report Date
Aug 22, 2022
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q1 FY2022-26.67%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q4 FY2021+11.11%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q4 FY2021+10.00%
Report Date
Nov 10, 2021
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Q2 FY2021-2.99%
Report Date
Jun 30, 2021
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q1 FY2021+5.19%
Report Date
Mar 31, 2021
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Q4 FY2020+0.00%
Report Date
Dec 31, 2020
EPS Beat/Miss
—
Price Before
$0.00
Price After
$0.00
Beat Rate0 / 8 quarters
Largest Move-26.67% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NPHC ends December
Nutra Pharma Corp. (NPHC) most recently reported earnings on September 30, 2022 for Q3 FY2022, posting EPS of $0.00 (in line with the analyst consensus of —).
Each quarter, investors track NPHC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NPHC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NPHC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NPHC earnings · 4 questionsNutra Pharma Corp.'s next earnings report is expected around TBD. NPHC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NPHC historically reports after market close (AMC).
NPHC earnings datewhen is NPHC earningsNPHC next earnings datewhen does NPHC report earningsNPHC earnings calendar
▸ Source: FMP · Nutra Pharma Corp. SEC filings · US GAAP · Nutra Pharma Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026